Notice of Change to the Eligibility Information for RFA-DA-22-001, "Mobile Health Solutions to rectify digital inequality in communities affected by drug addiction (R43/R44 Clinical Trial Optional)"
Notice Number:
NOT-DA-21-051

Key Dates

Release Date:

May 7, 2021

Related Announcements

RFA-DA-22-001 - Mobile Health Solutions to rectify digital inequality in communities affected by drug addiction (R43/R44 Clinical Trial Optional)

Issued by

National Institute on Drug Abuse (NIDA)

Purpose

This Notice informs applicants of a changes to the Eligibility Information Section for Funding Opportunity Announcement (FOA) RFA-DA-22-001, Mobile Health Solutions to rectify digital inequality in communities affected by drug addiction (R43/R44 Clinical Trial Optional)

 
The following Section of RFA-DA-22-001 has been modified to reflect the removal of the sentence in bold.

Currently Reads:

Section III. Eligibility Information

1. Eligible Applicants

Eligible Individuals (Program Director/Principal Investigator)

Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.

Under the SBIR program, for both Phase I and Phase II, the primary employment of the PD/PI must be with the small business concern at the time of award and during the conduct of the proposed project. For projects with multiple PDs/PIs, at least one must meet the primary employment requirement. Occasionally, deviations from this requirement may occur.

For the STTR program, the PD(s)/PI(s) may be employed with the SBC or the single, “partnering” non-profit research institution as long as s/he has a formal appointment with or commitment to the applicant SBC, which is characterized by an official relationship between the SBC and that individual. Such a relationship does not necessarily involve a salary or other form of remuneration The primary employment of the PD/PI must be with the SBC or the Research Institution (where they are PD/PI at) at the time of award and during the conduct of the proposed project. (removed paragraph)

Each PD/PI must commit a minimum of 10% effort to the project. (removed sentence)

The SF424 (R&R) SBIR/STTR Application Guide should be referenced for specific details on eligibility requirements. For institutions/organizations proposing multiple PDs/PIs, see Multiple Principal Investigators section of the SF424 (R&R) SBIR/STTR Application Guide.

Modified to Read:

Section III. Eligibility Information

1. Eligible Applicants

Eligible Individuals (Program Director/Principal Investigator)

Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.

Under the SBIR program, for both Phase I and Phase II, the primary employment of the PD/PI must be with the small business concern at the time of award and during the conduct of the proposed project. For projects with multiple PDs/PIs, at least one must meet the primary employment requirement. Occasionally, deviations from this requirement may occur.

The SF424 (R&R) SBIR/STTR Application Guide should be referenced for specific details on eligibility requirements. For institutions/organizations proposing multiple PDs/PIs, see Multiple Principal Investigators section of the SF424 (R&R) SBIR/STTR Application Guide.


All other aspects of this FOA remain the same.  

Inquiries

Please direct all inquiries to:

Leonardo Angelone, PhD
National Institute on Drug Abuse (NIDA)
Telephone: 301-827-5946
Email: leonardo.angelone@nih.gov

Julia Berzhanskaya, PhD
National Institute on Drug Abuse (NIDA)
Telephone: 301-594-6140
Email: julia.berzhanskaya@nih.gov


Weekly TOC for this Announcement
NIH Funding Opportunities and Notices